Biocon's insulin biosimilar Glargine gets preference in top US formulary

The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in July this year

An insulin biosimilar called Glargine, co-developed by Biocon Biologics and US pharma company Viatris, will be listed by pharmacy benefit management organisation Express Scripts as a preferred insulin brand  on its National Preferred Formulary for diabetic patients in the US.

Drug formularies are a set of generic and brand name medicines which are preferred by a health plan. They help patients in choosing a less expensive drug when a cheaper alternative could be used to treat a condition just as well.

“The inclusion of our interchangeable biosimilar insulin glargine in Express Scripts’ National Preferred Formulary (NPF) in the US is